[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610064":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":44,"collaborators":20,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":20,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NICU patients born less than 30 weeks gestational age","EXPERIMENTAL","All patients included in the study will be assigned to receive NIRS monitoring.",[13],"Device: NIRS Monitoring",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","NIRS Monitoring","The renal NIRS device is a non-invasive tool that uses near-infrared light to measure oxygen saturation various tissues. Renal NIRS sensors will be placed by 24 hours of the participants' admission.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Sourabh Verma, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Jordan Nelson, MD","CONTACT","3478223664","Jordan.nelson@nyulangone.org",[32],{"facility":5,"status":33,"city":34,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":20},"RECRUITING","New York","10016","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-74.00597,40.71427,{"lat":42,"lon":41},{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100610064","nirs-monitoring-in-the-nicu-and-aki-100610064",false,"NCT07222722","NIRS Monitoring in the NICU and AKI","Near Infrared Spectroscopy (NIRS) Monitoring as an Early Predictor of Acute Kidney Injury (AKI) in a Vulnerable Neonatal Intensive Care Unit (NICU) Population","Inclusion Criteria:\n\n* Any neonate less than 30 weeks in gestational age\n* Willingness and capacity of both adult parents\u002Fguardians to sign consent\n\nExclusion Criteria:\n\n* An infant with known congenital anomalies of the kidney (i.e., grade 4 or 5 vesicoureteral reflux (VUR), posterior urethral valves, moderate or severe hydronephrosis, autosomal recessive polycystic kidney disease (ARPKD), bilateral renal agenesis or dysplasia)\n* Age \\>30 weeks gestational age\n* Age \\\u003C24 weeks and \\\u003C500 grams (will be excluded due to sensitivity of skin in this vulnerable population).\n* Clinician's decision that NIRS is not suitable due to the patient's clinical condition",true,"ALL","24 Weeks","30 Weeks",{"count":58,"type":59},100,"ESTIMATED","INTERVENTIONAL",[62],"NA","The primary objective of this study is to describe the pattern of renal tissue oxygen saturation (SrSO2) using near-infrared spectroscopy (NIRS) in premature infants \\\u003C30 weeks gestational age. The secondary objective of this study is to evaluate prenatal and postnatal risk factors for acute kidney injury (AKI) in premature infants \\\u003C30 weeks gestational age. The investigators will also compare various rates of complications including death, length-of-stay, and prolonged duration of mechanical ventilation, among others.",[65,66],"Acute Kidney Injury (AKI)","Postnatal AKI","2025-10-29",{"date":69,"type":70},"2025-10-30","ACTUAL",{"date":72,"type":59},"2025-11",{"date":74,"type":59},"2026-04-01",{"name":5,"class":6},1]